Sanara MedTech ((SMTI)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sanara MedTech’s latest earnings call struck an upbeat tone, with management emphasizing strong double‑digit revenue growth, record margins, and a return to GAAP profitability. While acknowledging higher operating and interest costs and some pressure on cash, executives argued that expanding distribution and disciplined capital use position the company for sustained, profitable growth.
Strong Revenue Growth From Core Soft Tissue Portfolio
Sanara posted a 19% year‑over‑year rise in Q1 2026 net revenue, adding $4.4 million versus the prior year. The increase was driven mainly by higher demand for soft tissue repair products such as CellerateRX Surgical and BIASURGE, underscoring continued traction in core wound and surgical applications.
GAAP Net Profitability Marks A Key Milestone
The company turned the corner on profitability, reporting GAAP net income from continuing operations of $0.4 million, or $0.04 per diluted share. This compares with a net loss of $0.6 million, or $0.07 per share, in Q1 2025, signaling improved operating leverage as the business scales.
Margins Expand As Operating Income Rises Sharply
Gross profit climbed 20% to $25.9 million, with gross margin improving by about 100 basis points to roughly 93% of net revenue. Operating income rose $1.8 million to $2.6 million, reflecting tighter cost control and the high‑margin nature of Sanara’s product mix.
Adjusted EBITDA Surges, Highlighting Underlying Strength
Adjusted EBITDA jumped 58% year‑over‑year to $4.3 million in Q1 2026, an improvement of $1.6 million. Management pointed to this metric as evidence that cash‑generating capacity is strengthening even as the company continues to invest in commercial expansion.
Broader Commercial Reach And Distribution Footprint
Sanara’s products are now contracted or approved in more than 4,000 hospitals and ambulatory surgery centers, and sold in over 1,400 facilities versus more than 1,300 a year ago. Distributor agreements also expanded to over 450 from 400, broadening the company’s access to end customers and supporting future growth.
Sales Force Expansion Drives Record Monthly Performance
The sales team has grown to 43 representatives, supporting deeper market coverage and physician engagement. Management noted that March was the strongest sales month in company history, excluding an earlier hurricane‑related anomaly in October 2024, underscoring growing market penetration.
Capital Allocation And Cash‑Flow Discipline Improve
Sanara paid all debt service in cash during the quarter, moving away from prior payment‑in‑kind usage and signaling better free cash flow generation. Capital is being directed primarily toward organic growth and selected R&D initiatives, with the OsStic program highlighted as on track for a Q1 2027 market debut.
Cash Usage Ticks Up As Operating Needs Grow
Cash on hand declined to $13.6 million as of March 31, 2026 from $16.6 million at year‑end, reflecting investment and working capital needs. Net cash used in operating activities rose modestly to $2.5 million from $2.0 million in the prior‑year quarter, a trend investors will watch as growth initiatives continue.
Higher Interest And Other Costs Pressure The Bottom Line
Other expense increased to $2.2 million from $1.4 million year‑over‑year, largely due to greater interest expense and fees tied to the CRG term loan. The company also recorded a higher share of losses from equity‑method investments, partially offsetting the benefits of stronger operating performance.
Operating Expenses Climb With SG&A Investments
Operating expenses rose 12% to $23.2 million, representing 83.6% of sales, as Sanara invested more heavily in selling, general, and administrative functions. This spending was only partly offset by lower R&D costs, reflecting the company’s focus on scaling its commercial infrastructure.
R&D Dips Temporarily, Raising Execution Questions
R&D expense slipped to $0.8 million, or 2.7% of sales, from $0.9 million, or 4.1% of sales, a year earlier, creating a near‑term pullback. Management reiterated a target of 5%–7% of sales for annual R&D, but acknowledged quarter‑to‑quarter fluctuations could pose execution risks if underinvestment persists.
Operational Disruption And Seasonally Soft Quarter Managed
The quarter included a three‑day weather‑related shutdown in January that reduced shipping days and temporarily weighed on sales. Management also reminded investors that Q1 is historically the slowest quarter for the business, making the double‑digit revenue growth particularly notable.
New Reps And Vizient Contract Still In Early Ramp
Recently added sales representatives and the new Vizient group purchasing organization relationship have not yet fully contributed to results. Management expects it will take roughly six months for new reps to reach material productivity and more time for facility‑level work to unlock the full benefits of the Vizient agreement.
Guidance Reaffirmed On Back Of Strong Start To 2026
Sanara reaffirmed Q2 2026 net revenue guidance of $28.5 million to $29.5 million, implying about 10%–14% growth year‑over‑year. Full‑year 2026 guidance of $116 million to $121 million, or roughly 13%–17% growth, is underpinned by Q1’s 19% revenue increase, 93% gross margin, positive GAAP earnings, and expanding commercial presence.
Sanara MedTech’s earnings call painted the picture of a company moving firmly into profitable growth, supported by premium margins and a growing sales and distribution network. While higher operating and interest costs and a modest cash draw remain watch points, reaffirmed guidance and clear investment priorities suggest management is confident in sustaining momentum through 2026 and beyond.